Delivery Order SPE2DR25D9144-SPE2DR26FDJM2

The Defense Logistics Agency awarded a delivery order valued at $11,771.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nuplazid 34 mg capsules (30-count units). This firm fixed-price delivery order, issued on January 12, 2026, with an ultimate completion date of February 3, 2026, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with DLA, the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established to streamline pharmaceutical supply chains for Department of Defense military healthcare facilities worldwide.

DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and established performance record to distribute a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables to DoD healthcare operations. The parent PPV-G GEN V contract, valued at $499.999 billion with a completion date of December 31, 2036, represents part of a $30.3 billion acquisition strategy and positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors. The company's extensive product portfolio and demonstrated capability across multiple therapeutic categories underscore its role in supporting recurring medical supply needs across the military healthcare system.